U.S. markets open in 6 hours 55 minutes

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.03-0.04 (-0.28%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close14.07
Bid0.00 x 3100
Ask0.00 x 4000
Day's Range13.94 - 14.07
52 Week Range13.91 - 19.97
Avg. Volume2,202,146
Market Cap44.125B
Beta (5Y Monthly)1.10
PE Ratio (TTM)11.64
EPS (TTM)1.21
Earnings DateN/A
Forward Dividend & Yield0.84 (5.95%)
Ex-Dividend DateMar 30, 2021
1y Target Est20.37
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
93% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TAK

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Takeda Pharmaceutical Company L
    Analyst Report: Roche Holding AGRoche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 60% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Benzinga

    Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs

    Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for central nervous system (CNS) indications over a four-year research term. Under terms of the amendment, Takeda will pay Wave $22.5 million for collaboration-related research and preclinical expenses. The amendment allows Wave to advance or partner CNS programs, including those using ADAR editing, outside o

  • Benzinga

    Calithera Buys Two Oncology Candidates From Takeda For $45M

    Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a total upfront cash payment to Takeda of $10 million and $35 million in Calithera Series A preferred stock. Additionally, Takeda will be eligible to receive milestone payments across both programs. Calithera will pay tiered royalties of high single-digits to low teens on future net sales. The first compou

  • Zacks

    Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry

    Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.